Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04BXX
|
|||
| Former ID |
DIB001510
|
|||
| Drug Name |
AN-019
|
|||
| Synonyms |
NRC-19; NRC-24; NRC-AN-015; NRC-AN-019; Bcr-Abl inhibitors (CML), Natco
Click to Show/Hide
|
|||
| Indication | Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.1; ICD-9: 205.1] | Phase 2 | [1] | |
| Company |
Natco Pharma Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031662) | |||
| REF 2 | Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.